Ask about this productRelated genes to: BMP13 protein
- Gene:
- GDF6 NIH gene
- Name:
- growth differentiation factor 6
- Previous symbol:
- SGM1
- Synonyms:
- BMP13, KFS, KFS1
- Chromosome:
- 8q22.1
- Locus Type:
- gene with protein product
- Date approved:
- 1999-04-23
- Date modifiied:
- 2014-11-18
Related products to: BMP13 protein
Related articles to: BMP13 protein
- Mesenchymal stromal cells (MSCs) are widely used in human cell-based therapies and recent research is focused on the use of MSCs in equine regenerative medicine. Recently, MSCs have been isolated from equine follicular aspirates; however, a major concern during isolation is the potential contamination with fibroblasts, the predominant stromal cell type in many tissues. Furthermore, both cell types share the minimal criteria established by the International Society for Cellular Therapy (ISCT) for MSCs identification. Hence, our study aimed to compare the morphological characteristics, expansion behavior, immunophenotype, differentiation capacity and gene expression profiles of equine MSCs obtained from follicular aspirates and a commercial equine dermal fibroblast cell line. Under standard culture conditions, both cell lines exhibited a spindle-like morphology, expressed mesenchymal markers such as CD90 or CD29, and lacked the expression of CD45, CD19 and MHC-II, and manifested trilineage differentiation, however the chondrogenic differentiation was less evident in fibroblasts. Transcriptomic analysis using an RT² Profiler PCR Array revealed 35 differentially expressed genes between MSCs and fibroblasts. These results were further validated by quantitative PCR analysis: while fibroblasts showed higher expression of ANPEP, PROM1 and SOX2, genes like FGF2, LIF and KDR were downregulated in these cells. Moreover, GDF6, a key factor for MSCs differentiation, was markedly downregulated in fibroblasts. In conclusion, our results demonstrate that conventional criteria, including morphology, immunophenotyping, differentiation assays, and gene expression analysis, are insufficient to unequivocally identify MSCs. These findings underscore the need to implement additional experimental approaches to confidently discriminate between MSCs and fibroblasts. - Source: PubMed
Publication date: 2026/04/02
Del Prado Soriano-Campos MaríaMuñoz-García Carmen CristinaLuis-Calero MarcosGallardo-Soler AlejandroGonzález-Fernández LauroMacías-García Beatriz - The greater amberjack () is a globally important aquaculture fish species belonging to the family Carangidae. However, current research on the ovarian development and regulation of the greater amberjack is limited, particularly with regard to early ovarian development in artificially bred individuals. Therefore, this study aims to analyze the ovarian transcriptomes at the primary growth stage in one-year-old fish at the chromatin nucleolar stage and two-year-old fish at the perinucleolar stage to suggest how early ovarian development takes place in artificially bred greater amberjacks. To do this, the study constructed ovarian mRNA expression profiles of different stages of artificially bred fish and identified differentially expressed genes (DEGs), Gene Ontology terms, and Kyoto Encyclopedia of Genes and Genomes pathways important for various physiological processes. A functional analysis revealed that the DEGs closely related to ovarian development were involved in cell growth and death (e.g., , , , , , and ), the TGF-beta signaling pathway (e.g., , , , , , and ), steroid hormone biosynthesis (e.g., , , and ), and the endocrine system (e.g., , , , and ). These findings suggest that ovarian development is the result of the coordinated regulation of various genes responsible for various functions. This study provides a theoretical basis for exploring the underlying molecular mechanisms of early ovarian development in artificially bred greater amberjacks. - Source: PubMed
Publication date: 2026/02/25
Deng QiuxiaHuang YangRu XiaoyingLin HaoyiYou XinxinHao RuijuanLi HangHu QinZhang DongyingZhao YanfeiWu JinhuiLi GuangliZhu Chunhua - To highlight the key translational advances and interdisciplinary discussions from the 2025 University of Debrecen Musculoskeletal Symposium (UD-MUSK), focusing on osteoarthritis (OA) and related musculoskeletal (MSK) diseases. - Source: PubMed
Publication date: 2025/12/11
Kovács PatrikVágó JuditMobasheri AliJenei-Lanzl ZsuzsaZaucke FrankMadry HenningCsernoch LászlóSzekanecz ZoltánSzondy ZsuzsaSzöőr ÁrpádSzatmari IstvanOláh TamásMatta Csaba - Cardiac hypertrophy, a key feature and predisposing factor of heart failure, is mainly controlled by complex signaling cascades. Growth differentiation factor 6 (GDF6) plays critical roles in cell growth and cardiovascular homeostasis; however, its role and underlying mechanisms in cardiac hypertrophy remain unclear. Mice were intravenously injected with adeno-associated virus serotype 9 to overexpress and knock down GDF6 in murine hearts and then exposed to transverse aortic constriction (TAC) surgery to generate pressure overload-induced cardiac hypertrophy. Echocardiographic, histological, and molecular analyses were performed to decipher the alterations to cardiac hypertrophy. In addition, neonatal rat ventricular myocytes (NRVMs) were isolated and stimulated with phenylephrine (PE) to further validate its involvement in hypertrophic growth of cardiomyocytes. GDF6 expression was elevated in murine hearts and NRVMs by ROS production under hypertrophic stimuli. GDF6 knockdown aggravated, while GDF6 overexpression attenuated, pressure overload-induced cardiac hypertrophy, inflammation, and dysfunction in vivo. Meanwhile, we found that GDF6 also prevented PE-induced hypertrophic growth of NRVMs in vitro. Mechanistically, GDF6 activated AMPKα to exert cardioprotective effects, and AMPKα inhibition significantly blocked the anti-hypertrophic effects of GDF6. Further studies showed that GDF6 activated AMPKα through the cAMP/Epac1 pathway, and that Epac1 knockdown abolished the protective effects of GDF6 against TAC- or PE-induced cardiac hypertrophy in vivo and in vitro. In general, our findings, for the first time, define GDF6 as a negative regulator of cardiac hypertrophy and show that supplementation of GDF6 may be of great therapeutic interest for heart failure. - Source: PubMed
Publication date: 2025/11/29
Ren QuanWang ZhiweiRen Wei - To identify potential biomarkers for laryngeal cancer and investigate their effects on the characteristics of laryngeal cancer cells. - Source: PubMed
Publication date: 2025/12/03
Zhu HengtaoLiang CaihongLiu YuguiLuo QingJiang Hongqun